Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vaidyane Ayurved Laboratories's Revenue for the
six
months ended in Mar. 2026 was ₹570 Mil. Vaidyane Ayurved Laboratories's average Accounts Receivable for the
six
months ended in Mar. 2026 was ₹90 Mil.
Hence, Vaidyane Ayurved Laboratories's Receivables Turnover for the
six
months ended in Mar. 2026 was 6.31.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vaidyane Ayurved Laboratories Receivables Turnover Related Terms
Vaidyane Ayurved Laboratories Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MADHAVBAUG vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Receivables Turnover of 6.31 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vaidyane Ayurved Laboratories and its competitors. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #91 out of 948 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is Vaidyane Ayurved Laboratories' Receivables Turnover too high?
Vaidyane Ayurved Laboratories' current Receivables Turnover is 6.31. The Drug Manufacturers industry median Receivables Turnover is 5.07. Vaidyane Ayurved Laboratories' value of 6.31 is 24.5% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #91 out of 948 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #91 out of 948 companies for Receivables Turnover. This places Vaidyane Ayurved Laboratories in the top 10% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Vaidyane Ayurved Laboratories' value of 6.31 is 24.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Receivables Turnover of 6.31 is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Receivables Turnover is 6.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.21, compared to a current price of ₹188.85 — trading 17.2% below its estimated fair value. The current Receivables Turnover is 6.31 and 24.5% above the Drug Manufacturers industry median of 5.07. Vaidyane Ayurved Laboratories' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Receivables Turnover is 6.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹188.85 is trading 17.2% below its estimated GF Value™ of ₹228.21.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
Receivables Turnover: 6.31
GF Value™: ₹228.21 vs. price of ₹188.85 (17.2% below fair value)
Industry Position: 24.5% above the Drug Manufacturers median (#91 of 948)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
77GF Score
Get the complete analysis for NSE:MADHAVBAUG
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
